Rejuvenon

About Rejuvenon

Rejuveron Life Sciences AG is a Zurich-based biotechnology firm operating as a platform company dedicated to advancing therapies that target the fundamental mechanisms of aging. The company was co-founded by the notable entrepreneur and investor Christian Angermayer, who established it as part of his broader 'Next Human Agenda' to extend healthy human lifespans. Angermayer's personal interest in longevity and his extensive background in building and investing in biotech and technology companies through his family office, Apeiron Investment Group, provide the strategic foundation for Rejuveron. He perceived a gap in the market for entities focused specifically on developing therapeutics for aging, which he views as a treatable disease, leading to the creation of Rejuveron.

The company's business model centers on creating a portfolio of subsidiary biotech companies, or 'Rejuverettes'. Rejuveron acquires promising early-stage technologies and assets from academic labs and other research institutions, building a dedicated team around each one to accelerate its development through preclinical and clinical stages. This model allows for a diversity of approaches to treating age-related diseases and fosters cross-pollination of ideas across its portfolio. The ultimate goal is to develop and commercialize medical drugs that can significantly prolong both life and health spans. Rejuveron operates in both preclinical and clinical research areas, aiming to translate complex aging science into viable drug candidates. The company's financial strategy involves significant venture capital investment to fund these long-term, capital-intensive research and development projects.

Rejuveron's core service is the development of a pipeline of therapeutics targeting what are known as the 'hallmarks of aging'. By focusing on aging as the root cause of many prevalent illnesses, the company addresses a market that theoretically includes the entire population. One of its key scientific figures is Professor Manuel Serrano, who was instrumental in defining these hallmarks. The company’s strategy involves targeting standard diseases alongside aging, recognizing the regulatory challenge that aging itself is not yet classified as a disease by bodies like the FDA. This approach allows for more immediate clinical pathways while pursuing the long-term objective of creating rejuvenation therapies that could enable individuals to live well into their 100s with the vitality of a much younger person.